Related Experiment Video
Updated: Nov 18, 2025
08:16
Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies
Published on: October 6, 2022
7.0K
Amorfrutins Relieve Neuropathic Pain through the PPARγ/CCL2 Axis in CCI Rats.
Pengfei Gao1, Jiayu Wang1, Zhen Su1
1Department of Anesthesiology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaian, China.
PPAR Research
|February 8, 2021
Summary
Amorfrutins effectively reduce neuropathic pain in rats by suppressing inflammation and chemokine expression. This pain relief is linked to the activation of the PPAR-gamma pathway, suggesting a new therapeutic target.
Area of Science:
- Pharmacology and Toxicology
- Neuroscience
- Immunology
Background:
- Neuropathic pain is a significant global health issue with limited effective and safe pharmaceutical treatments.
- Current treatments for neuropathic pain often lack efficacy and can have adverse side effects.
- Understanding the molecular mechanisms underlying neuropathic pain is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the efficacy of amorfrutins in alleviating neuropathic pain.
- To elucidate the molecular mechanisms, specifically the role of proinflammatory cytokines and chemokines, involved in amorfrutin's therapeutic effects.
- To determine the involvement of the PPAR-gamma (PPARγ) pathway in mediating the antihyperalgesic effects of amorfrutins.
Main Methods:
- Evaluation of nociceptive responses in Chronic Constriction Injury (CCI) rat model of neuropathic pain.
- Enzyme-Linked Immunosorbent Assay (ELISA) to quantify the expression of key proinflammatory cytokines (TNFα, IL-6, IL-1β) and chemokines (CCL2/CCR2) in the spinal cord.
- Assessment of the effect of a PPARγ antagonist (GW9662) on amorfrutin-induced pain relief.
Main Results:
- Amorfrutins significantly reduced pain behaviors in CCI rats.
- Amorfrutins suppressed the expression of spinal cord proinflammatory cytokines (TNFα, IL-6, IL-1β) and the CCL2/CCR2 chemokine pathway.
- The antihyperalgesic effect of amorfrutins was reversed by co-administration of the PPARγ antagonist GW9662, indicating a crucial role for PPARγ activation.
Conclusions:
- Amorfrutins demonstrate significant potential for treating neuropathic pain by inhibiting inflammation and chemokine expression.
- The therapeutic effects of amorfrutins are mediated through the activation of the PPARγ pathway.
- The PPARγ-CCL2/CCR2 pathway represents a promising novel therapeutic target for managing neuropathic pain.
Related Concept Videos
01:44Nociception
32.3K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
32.3K
01:25Analgesia and Pain Management
1.1K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.1K